Company news
Actinogen Medical Limited (ASX:ACW) news
Every Actinogen Medical Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ACW unlisted options fully underwritten
August 31, 2026
ACW FY2026 results and outlook
August 27, 2026
June 2026 Quarterly activity report & Appendix 4C
July 29, 2026
Xanamem depression trial published in British J Psychiatry
July 19, 2026
ACW third positive XanaMIA trial data committee review
June 17, 2026
Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
May 28, 2026
Actinogen receives positive scientific advice from EMA
May 27, 2026
Correction-March2026 quarterly activity report & Appendix 4C
April 28, 2026
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
April 1, 2026
ACW XanaMIA Alzheimers open label trial commences
March 31, 2026
ACW successfully completes $16.8m Placement and SPP
February 26, 2026
ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
February 25, 2026
Actinogen HY2025 financial report and Appendix 4D
February 25, 2026
ACW receives further $1.9m FY2025 R&D rebate from ATO
February 10, 2026
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivota...
February 2, 2026
ACW secures funding beyond XanaMIA AD trial final results
February 1, 2026
ACW December 2025 quarterly activity report & Appendix 4C
January 29, 2026
Continuation of Trading Halt
January 29, 2026
ACW positive XanaMIA Interim Analysis outcome
January 29, 2026
Trading Halt
January 28, 2026
Actinogen secures $4.3m of non-dilutive R&D tax funding
January 26, 2026
Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
December 18, 2025
ACW XanaMIA trial fully enrolled with 246th participant
December 17, 2025
ACW positive XanaMIA Data Monitoring Committee meeting
November 12, 2025
ACW September 2025 quarterly activity report & Appendix 4C
October 22, 2025
ACW confirms eligibility for further $1.9m RDTI
October 20, 2025
ACW achieves early screening closure for XanaMIA trial
October 19, 2025
ACW receives initial $5.5m R&D tax incentive rebate
October 14, 2025
Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a fu...
September 15, 2025
ACW successful FDA meeting on Alzheimers program
September 14, 2025
Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states
August 27, 2025
ACW pharmacokinetics trial success
August 26, 2025
ACW FY2025 results - accelerating Alzheimers pivotal trial
August 25, 2025
ACW Appendix 4E and 2025 annual report
August 25, 2025
Actinogen June 2025 quarterly activity report & Appendix 4C
July 29, 2025
A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US
July 22, 2025
Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
June 30, 2025
ACW accesses up to $13.8m in non-dilutive R&D tax funding
June 29, 2025
ACW 100th AD trial participant & interim analysis timeline
June 29, 2025
Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news
April 30, 2025
Actinogen March 2025 quarterly activity report & Appendix 4C
April 29, 2025
ACW conducts Type C meeting with FDA regarding depression
March 27, 2025
ACW HY25 results Advancing to latestage clinical development
February 24, 2025
Peer-reviewed clinpharm manuscript published
February 6, 2025
ACW December 2024 quarterly activity report & Appendix 4C
January 28, 2025
ACW randomizes first US participant in Alzheimers trial
December 8, 2024
Actinogen receives $9.0 million R&D tax incentive rebate
November 11, 2024
ACW September 2024 quarterly activity report & Appendix 4C
October 29, 2024
$3.0 million share purchase plan closes 1.3x oversubscribed
October 10, 2024
ACW $11.1m capital raising to accelerate Alzheimers trial
September 18, 2024